Related Experiment Videos

Atorvastatin calcium plus amlodipine for the treatment of hypertension

Antonia Delgado-Montero1, Jose L Zamorano

  • 1University Hospital Ramón y Cajal, Carretera de Colmenar Km 9.100, Madrid 28034, Spain.

Expert Opinion on Pharmacotherapy
|November 13, 2012
PubMed

Insights

A new single-pill combination of amlodipine and atorvastatin effectively treats hypertension and dyslipidemia. This fixed-dose formulation improves patient adherence and cardiovascular risk management.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Hypertension (HTN) and dyslipidemia (DYL) are key modifiable cardiovascular (CV) risk factors.
  • Concurrent HTN and DYL significantly elevate overall CV risk.
  • Complex drug regimens often lead to poor patient adherence to treatment guidelines.

Purpose of the Study:

  • To introduce and review the first fixed-dose combination pill containing an antihypertensive and a lipid-lowering agent.
  • To summarize clinical evidence supporting the use of amlodipine besylate and atorvastatin calcium single-pill combination (SPAA).

Main Methods:

  • Review of pharmacokinetic and pharmacodynamic properties of amlodipine and atorvastatin.
  • Analysis of data from randomized clinical trials and real-world observational studies of the SPAA formulation.

Main Results:

  • The single-pill combination (SPAA) demonstrates proven efficacy and tolerability.
  • SPAA offers a cost-effective treatment option.
  • Improved patient compliance is a key advantage of this combined formulation.

Conclusions:

  • Single-pill amlodipine and atorvastatin is a suitable option for managing hypertensive patients with DYL or high CV risk.
  • This combination addresses the need for simplified treatment regimens.
  • SPAA enhances treatment adherence and contributes to better CV risk burden management.
Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...